Trillium Therapeutics (NASDAQ: TRIL) and Windtree Therapeutics (OTCMKTS:WINT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.

Insider & Institutional Ownership

47.5% of Trillium Therapeutics shares are held by institutional investors. Comparatively, 0.3% of Windtree Therapeutics shares are held by institutional investors. 3.5% of Windtree Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Trillium Therapeutics and Windtree Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Trillium Therapeutics N/A N/A -$23.96 million ($3.79) -2.74
Windtree Therapeutics $2.04 million 8.06 -$39.49 million ($3.59) -0.07

Trillium Therapeutics has higher earnings, but lower revenue than Windtree Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Trillium Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Trillium Therapeutics and Windtree Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trillium Therapeutics 0 0 3 0 3.00
Windtree Therapeutics 0 1 0 0 2.00

Trillium Therapeutics presently has a consensus target price of $12.50, indicating a potential upside of 20.19%. Given Trillium Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Trillium Therapeutics is more favorable than Windtree Therapeutics.

Profitability

This table compares Trillium Therapeutics and Windtree Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trillium Therapeutics N/A -248.39% -65.21%
Windtree Therapeutics -1,205.47% N/A -345.52%

Summary

Trillium Therapeutics beats Windtree Therapeutics on 8 of the 12 factors compared between the two stocks.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.